Skip to main content

Educational Materials on Market Access

General introduction and country-specific seminars about market access for medical devices and IVD tests

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

One hundred fifty-six applications for innovation funding were received in Germany

On April 22, 2025, the Innovation Committee at the Federal Joint Committee (G-BA) announced the receipt of 156 applications (project ideas) for innovation funding of projects for new forms of care.

Of these, 117 applications were received in response to topic-specific funding calls:

  • Integration of AI systems into healthcare structures and processes: 39;
  • Strengthening child and youth health: 37;
  • Women's health: 21;
  • Dementia in outpatient care: 14;
  • Multimodal pain therapy in outpatient care: 6.

An additional 39 applications were submitted under the open-topic funding call.

The Innovation Committee is expected to decide in the fourth quarter of 2025 which project ideas will be invited to submit full proposals.

The relevant funding announcements were published on January 24, 2025, with the submission deadline on April 15, 2025.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.